Finally, although GPNMB blockade modestly extends the survival of tumor-bearing mice, combining GPNMB inhibition with standard-of-care therapies (e.g., radiotherapy and chemotherapy) or targeting the downstream PYK2/RSK2 signaling axis may enhance translational relevance and therapeutic efficacy. The gene discussed is RPS6KA3; the disease is neoplasm.